Gay Francesca, Marchetti Edoardo, Bertuglia Giuseppe
Division of Hematology, AOU Città della Salute e della Scienza, Department of Molecular Biotechnology and Health Science, University of Torino, Torino, Italy.
Hematol Oncol. 2025 Jun;43 Suppl 2(Suppl 2):e70067. doi: 10.1002/hon.70067.
Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. The current treatment landscape for multiple myeloma involves a combination of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem cell transplantation, which have significantly improved survival outcomes in recent years. However, the disease remains challenging, particularly in relapsed and refractory cases. Ongoing clinical trials are evaluating new therapeutic options, including chimeric antigen receptor T cell therapy, bispecific antibodies, antibody drug conjugate and novel agents like Cereblon E3 Ligase Modulatory Drugs. This review summarizes the key diagnostic criteria, prognostic features, response assessment for MM and highlights the current treatment landscape.
多发性骨髓瘤（MM）是一种血液系统恶性肿瘤，其特征为骨髓中浆细胞的克隆性增殖。目前多发性骨髓瘤的治疗方案包括蛋白酶体抑制剂、免疫调节药物、单克隆抗体和自体干细胞移植的联合应用，近年来这些治疗方法显著改善了生存结局。然而，该疾病仍然具有挑战性，尤其是在复发和难治性病例中。正在进行的临床试验正在评估新的治疗选择，包括嵌合抗原受体T细胞疗法、双特异性抗体、抗体药物偶联物以及像脑啡肽酶E3连接酶调节药物这样的新型药物。本综述总结了MM的关键诊断标准、预后特征、疗效评估，并重点介绍了当前的治疗格局。
